Turning Point Brands Q2 Earnings Call Highlights

Impact · against what's priced in

Turning Point Brands is seeing a significant structural pivot as Modern Oral now accounts for 48% of sales, leading to a substantial raise in segment revenue guidance. While aggressive spending to capture market share has halved adjusted EBITDA, the long-term margin potential from U.S. manufacturing remains a key upside catalyst.

TPB+0.40

No priced-in read yet

In context

The company raised its 2026 Modern Oral net sales forecast to $260M–$270M from $210M–$225M, confirming a successful pivot as the segment now represents 48% of total sales. This growth is offset by a 50% year-over-year decline in adjusted EBITDA to $15 million due to heavy investments in sales and marketing.

• ebitda▲104%
• guidance▲17%
• earnings▲5%
• TPB
• consumer staples
• fda
• nicotine pouches